Literature DB >> 10331402

Increased beta-cell proliferation and reduced mass before diabetes onset in the nonobese diabetic mouse.

S Sreenan1, A J Pick, M Levisetti, A C Baldwin, W Pugh, K S Polonsky.   

Abstract

To determine whether loss of beta-cell mass and function in the NOD mouse occurs gradually, beginning after the onset of insulitis, or abruptly, just before the onset of overt diabetes, beta-cell mass and rates of beta-cell proliferation and insulin secretory responses from the perfused pancreas were measured in NOD and control NOD/Scid mice at 8-9, 13, and 18 weeks of age. Of the NOD mice, 11 and 70% had diabetes (fasting blood glucose >8.3 mmol/l) at 13 and 18 weeks of age, respectively. Beta-cell mass in 8-week-old NOD mice was 69% of control mice (P>0.05), but the rate of 5-bromo-2-deoxyuridine uptake was greater, suggesting a compensatory proliferative response to ongoing autoimmune beta-cell destruction. Despite an increase in the rate of beta-cell proliferation, beta-cell mass was significantly reduced by 42% in 13-week-old nondiabetic NOD mice and by 73% in 18-week-old diabetic NOD mice. Insulin secretory responses to glucose and arginine demonstrated reductions of similar magnitude. In 18-week-old diabetic NOD mice, insulin secretion was reduced to a greater degree than beta-cell mass, suggesting the presence of beta-cell dysfunction in addition to reduced mass. These results suggest that in the NOD mouse, beta-cell destruction begins soon after the onset of insulitis. Despite a compensatory beta-cell proliferative response, beta-cell mass progressively falls and is significantly reduced by 13 weeks despite normal blood glucose concentrations. Diabetes may be present when residual beta-cell mass represents 30% of control levels.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10331402     DOI: 10.2337/diabetes.48.5.989

Source DB:  PubMed          Journal:  Diabetes        ISSN: 0012-1797            Impact factor:   9.461


  75 in total

1.  Evidence of increased islet cell proliferation in patients with recent-onset type 1 diabetes.

Authors:  A Willcox; S J Richardson; A J Bone; A K Foulis; N G Morgan
Journal:  Diabetologia       Date:  2010-06-09       Impact factor: 10.122

2.  Reversal of established autoimmune diabetes by restoration of endogenous beta cell function.

Authors:  S Ryu; S Kodama; K Ryu; D A Schoenfeld; D L Faustman
Journal:  J Clin Invest       Date:  2001-07       Impact factor: 14.808

3.  Modification of adverse inflammation is required to cure new-onset type 1 diabetic hosts.

Authors:  Maria Koulmanda; Ejona Budo; Susan Bonner-Weir; Andi Qipo; Prabhakar Putheti; Nicolas Degauque; Hang Shi; Zhigang Fan; Jeffrey S Flier; Hugh Auchincloss; Xin Xiao Zheng; Terry B Strom
Journal:  Proc Natl Acad Sci U S A       Date:  2007-08-01       Impact factor: 11.205

Review 4.  Beta cell mass in diabetes: a realistic therapeutic target?

Authors:  J J Meier
Journal:  Diabetologia       Date:  2008-03-04       Impact factor: 10.122

5.  Questioning four preconceived ideas on immunotherapy of clinical type 1 diabetes: lessons from recent CD3 antibody trials.

Authors:  Lucienne Chatenoud; Jean-François Bach
Journal:  Rev Diabet Stud       Date:  2005-11-10

6.  β Cells that Resist Immunological Attack Develop during Progression of Autoimmune Diabetes in NOD Mice.

Authors:  Jinxiu Rui; Songyan Deng; Arnon Arazi; Ana Luisa Perdigoto; Zongzhi Liu; Kevan C Herold
Journal:  Cell Metab       Date:  2017-02-09       Impact factor: 27.287

Review 7.  Metabolic abnormalities in the pathogenesis of type 1 diabetes.

Authors:  Shuyao Zhang; Clayton E Mathews
Journal:  Curr Diab Rep       Date:  2014       Impact factor: 4.810

8.  Curative and beta cell regenerative effects of alpha1-antitrypsin treatment in autoimmune diabetic NOD mice.

Authors:  Maria Koulmanda; Manoj Bhasin; Lauren Hoffman; Zhigang Fan; Andi Qipo; Hang Shi; Susan Bonner-Weir; Prabhakar Putheti; Nicolas Degauque; Towia A Libermann; Hugh Auchincloss; Jeffrey S Flier; Terry B Strom
Journal:  Proc Natl Acad Sci U S A       Date:  2008-10-13       Impact factor: 11.205

Review 9.  Clinical immunologic interventions for the treatment of type 1 diabetes.

Authors:  Lucienne Chatenoud; Katharina Warncke; Anette-G Ziegler
Journal:  Cold Spring Harb Perspect Med       Date:  2012-08-01       Impact factor: 6.915

Review 10.  Diabetes and cardiovascular autonomic dysfunction: application of animal models.

Authors:  Katia De Angelis; Maria Claudia Irigoyen; Mariana Morris
Journal:  Auton Neurosci       Date:  2008-12-02       Impact factor: 3.145

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.